📝 restructuring the content

content/1.research/index.md → content/1.research/1.index.md

@@ -1,23 +1,14 @@
 ---
-title: Peptide Research
+title: Overview
 description: Explore cutting-edge peptide therapeutics for metabolic disorders, including GLP-1 agonists, dual and triple receptor agonists, and innovative treatments for obesity and diabetes.
-navigation: false
+position: 1
 ---
 
 ::card-group
-  ::card
-  ---
-  title: Overview
-  to: /research/peptides/overview
-  icon: i-mdi-file-document-box-search
-  ---
-  Recent advancements in peptide therapies have led to the development of three promising treatments for obesity and type 2 diabetes: tirzepatide, retatrutide, and cagrilintide.
-  ::
-
   ::card
   ---
   title: Tirzepatide
-  to: /research/peptides/tirzepatide
+  to: /research/tirzepatide
   icon: i-mdi-medication
   ---
   A dual GIP/GLP-1 receptor agonist that significantly improves glycemic control and promotes substantial weight loss in patients with type 2 diabetes.
@@ -26,7 +17,7 @@ navigation: false
   ::card
   ---
   title: Retatrutide
-  to: /research/peptides/retatrutide
+  to: /research/etatrutide
   icon: i-mdi-medication
   ---
   An innovative triple-agonist peptide that targets GIP, GLP-1, and glucagon receptors, offering significant weight loss and metabolic benefits for patients with obesity and type 2 diabetes.
@@ -35,9 +26,16 @@ navigation: false
   ::card
   ---
   title: Cagrilintide
-  to: /research/peptides/cagrilintide
+  to: /research/cagrilintide
   icon: i-mdi-medication
   ---
   A cutting-edge, long-acting amylin receptor agonist that offers significant weight loss benefits and improved metabolic control for patients with obesity and type 2 diabetes.
   ::
+  ::card
+  ---
+  title: Dosage
+  to: /research/dosage
+  icon: i-mdi-medication
+  ---
+  Explore the optimal dosage regimens for our peptide therapeutics, including Tirzepatide, Retatrutide, and Cagrilintide, to maximize efficacy and minimize adverse events.
 ::

content/1.research/5.dosage.md

@@ -0,0 +1,43 @@
+---
+title: Dosage Information
+description: Comprehensive dosage guidelines for Tirzepatide, Retatrutide, and Cagrilintide, including when to consider dose increases.
+---
+
+## Tirzepatide Dosage
+
+| Dose Level | Weekly Dosage |
+|------------|---------------|
+| Starting   | 2.5 mg or 5 mg|
+| Level 1    | 7.5 mg        |
+| Level 2    | 10 mg         |
+| Maximum    | 15 mg         |
+
+## Retatrutide Dosage
+
+| Dose Level | Weekly Dosage (Example) |
+|------------|-------------------------|
+| Starting   | 1 mg or 2 mg            |
+| Level 1    | 4 mg                    |
+| Level 2    | 8 mg                    |
+| Maximum    | 12 mg                   |
+
+## Cagrilintide Dosage
+
+| Dose Level | Weekly Dosage (Example) |
+|------------|-------------------------|
+| Starting   | 0.3 mg or 0.6 mg        |
+| Level 1    | 1.2 mg                  |
+| Level 2    | 2.4 mg                  |
+| Maximum    | 4.5 mg                  |
+
+## When to Increase Dosage
+
+For all peptides (Tirzepatide, Retatrutide, and Cagrilintide), consider increasing the dosage if/when you feel the current dose is not as effective as it once was. Signs that may indicate a need for dose increase include:
+
+1. Plateauing weight loss
+2. Increased appetite or reduced feelings of fullness
+3. Diminished effects on blood sugar control (for patients with diabetes)
+
+Always consult with your healthcare provider before making any changes to your dosage. They will evaluate your individual response, tolerability, and overall health status to determine if a dose increase is appropriate and safe for you.
+
+Remember that dose increases should be gradual and follow the recommended titration schedule for each medication. Your healthcare provider will guide you through this process to minimize side effects and optimize the benefits of your treatment.